PM
ARCT icon

Prosight Management’s Arcturus Therapeutics ARCT Stock Holding History

Prosight Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-255,000
Closed -$6.11M – 38
2023
Q1 		$6.11M Buy
+255,000
New +$4.58M 2.9% 14

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prosight Management's ARCT Position: Q2 2023 in Review

Prosight Management sold out of Arcturus Therapeutics (ARCT) in Q2 2023, closing a stake of 255,000 shares — an estimated $6.11M sold.

Prosight Management first reported a position in ARCT in Q1 2023 and held it in 1 quarter. The position peaked at $6.11M in Q1 2023. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2023.

  • Prosight Management reported no remaining Arcturus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prosight Management sold 255,000 Arcturus Therapeutics shares in Q2 2023, an estimated $6.11M.
  • Prosight Management first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 1 quarter.
  • Prosight Management's Arcturus Therapeutics position peaked at $6.11M in Q1 2023.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2023.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.